Intuitive Surgical R&D increased by 2.6% to $361.90M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 14.5%, from $316.20M to $361.90M. Over 4 years (FY 2021 to FY 2025), R&D shows an upward trend with a 18.2% CAGR.
Higher spending signals a commitment to innovation and future product launches, whereas significant cuts may indicate a shift toward short-term profitability.
Research and development expenses represent the costs incurred to discover new products, improve existing technologies,...
Highly comparable across pharmaceutical and medical device peers, where R&D intensity is a key metric for long-term valuation.
research_and_development| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $162.30M | $165.50M | $183.40M | $210.50M | $207.30M | $217.10M | $244.10M | $244.90M | $244.40M | $249.40M | $260.10M | $284.50M | $280.10M | $286.00M | $294.70M | $316.20M | $313.30M | $329.40M | $352.90M | $361.90M |
| QoQ Change | — | +2.0% | +10.8% | +14.8% | -1.5% | +4.7% | +12.4% | +0.3% | -0.2% | +2.0% | +4.3% | +9.4% | -1.5% | +2.1% | +3.0% | +7.3% | -0.9% | +5.1% | +7.1% | +2.6% |
| YoY Change | — | — | — | — | +27.7% | +31.2% | +33.1% | +16.3% | +17.9% | +14.9% | +6.6% | +16.2% | +14.6% | +14.7% | +13.3% | +11.1% | +11.9% | +15.2% | +19.7% | +14.5% |